Form 8-K - Current report:
SEC Accession No. 0001628280-22-014127
Filing Date
2022-05-12
Accepted
2022-05-12 17:07:12
Documents
14
Period of Report
2022-05-12
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K mrtx-20220512.htm   iXBRL 8-K 81757
2 EX-99.1 exhibit991-mirati2022equit.htm EX-99.1 388556
6 image_0.jpg GRAPHIC 161
  Complete submission text file 0001628280-22-014127.txt   676233

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT mrtx-20220512.xsd EX-101.SCH 1909
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT mrtx-20220512_lab.xml EX-101.LAB 24275
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT mrtx-20220512_pre.xml EX-101.PRE 12646
8 EXTRACTED XBRL INSTANCE DOCUMENT mrtx-20220512_htm.xml XML 10544
Mailing Address 3545 CRAY COURT SAN DIEGO CA 92121
Business Address 3545 CRAY COURT SAN DIEGO CA 92121 858-332-3410
Mirati Therapeutics, Inc. (Filer) CIK: 0001576263 (see all company filings)

EIN.: 462693615 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35921 | Film No.: 22918878
SIC: 2834 Pharmaceutical Preparations